This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About DermTech Stock (NASDAQ:DMTK) 30 days 90 days 365 days Advanced Chart Get DermTech alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.05▼$0.4252-Week Range N/AVolume3.66 million shsAverage Volume1.07 million shsMarket Capitalization$3.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. Read More Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMTK Stock News HeadlinesDERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 10, 2025 | globenewswire.comNorth American Morning Briefing: TSMC Earnings -2-October 18, 2024 | morningstar.comMTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …August 30 at 2:00 AM | Weiss Ratings (Ad)DermTech, Inc. (DMTKQ)September 27, 2024 | finance.yahoo.comVictory RS Small Cap Growth ASeptember 8, 2024 | morningstar.comMWhy Is DermTech (DMTK) Stock Down 26% Today?June 24, 2024 | investorplace.comDermTech Files for Voluntary Chapter 11 ProtectionJune 18, 2024 | businesswire.comDMTK Stock Earnings: DermTech Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSee More Headlines DMTK Stock Analysis - Frequently Asked Questions How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.03. The firm had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.40 million. DermTech had a negative net margin of 572.19% and a negative trailing twelve-month return on equity of 138.79%. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Digital Turbine (APPS), Datadog (DDOG) and Cloudflare (NET). Company Calendar Last Earnings11/09/2021Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:DMTK CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$100.89 million Net Margins-572.19% Pretax Margin-572.19% Return on Equity-138.79% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.46 Sales & Book Value Annual Sales$15.66 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / BookN/AMiscellaneous Outstanding Shares34,963,000Free Float33,180,000Market Cap$3.29 million OptionableOptionable Beta2.48 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:DMTK) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DermTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.